Aurora Investment Counsel Decreases Stock Holdings in Royalty Pharma PLC $RPRX

Aurora Investment Counsel lowered its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 32.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,415 shares of the biopharmaceutical company’s stock after selling 16,861 shares during the period. Aurora Investment Counsel’s holdings in Royalty Pharma were worth $1,699,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Assetmark Inc. boosted its position in Royalty Pharma by 58.8% during the 1st quarter. Assetmark Inc. now owns 5,858 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 2,170 shares during the period. Financiere des Professionnels Fonds d investissement inc. raised its stake in shares of Royalty Pharma by 15.5% during the first quarter. Financiere des Professionnels Fonds d investissement inc. now owns 32,413 shares of the biopharmaceutical company’s stock valued at $1,555,000 after purchasing an additional 4,356 shares during the period. Bessemer Group Inc. lifted its position in shares of Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 282 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Royalty Pharma by 1.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 27,228 shares of the biopharmaceutical company’s stock valued at $1,329,000 after purchasing an additional 454 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Royalty Pharma during the 1st quarter valued at $298,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insider Buying and Selling

In other news, CFO Terrance P. Coyne sold 64,399 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total transaction of $3,476,258.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.06, for a total value of $726,073.04. Following the sale, the executive vice president owned 31,881 shares in the company, valued at $1,691,605.86. The trade was a 30.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 427,800 shares of company stock valued at $23,333,723. 18.84% of the stock is currently owned by insiders.

Royalty Pharma Trading Down 0.6%

NASDAQ RPRX opened at $58.18 on Friday. Royalty Pharma PLC has a one year low of $34.08 and a one year high of $59.44. The company has a 50-day simple moving average of $55.01 and a 200-day simple moving average of $48.52. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The firm has a market capitalization of $33.50 billion, a PE ratio of 39.58, a price-to-earnings-growth ratio of 10.30 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The firm had revenue of $630.58 million for the quarter, compared to analyst estimates of $881.69 million. On average, equities analysts forecast that Royalty Pharma PLC will post 5.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on RPRX. TD Cowen lifted their price target on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. raised their target price on Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Citigroup lifted their target price on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, UBS Group boosted their price target on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $56.57.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.